Clinical trials
EBV clinical trials
Below are recruiting ebv clinical trials, each written for real people, not researchers. We’re tracking 65 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06203314Recruiting
Epstein-Barr virus and cancer risk study
This study looks at how Epstein-Barr virus (a common virus) may be linked to cancer risk. If you live in Zhongshan or Wuzhou City and are generally healthy, you may be able to join and help researchers learn more.
Zhongshan, GuangdongAges 30–69 - NCT06321939Recruiting
Tracking EBV DNA in Blood for Nasopharyngeal Cancer
This trial studies whether tracking levels of Epstein-Barr virus DNA in your blood can help guide treatment for non-metastatic nasopharyngeal cancer. You would get standard radiation and maybe chemotherapy, with extra blood tests to see how the virus levels change.
Changsha, HunanAges 18 years+ - NCT06592599RecruitingPhase 2
Drug combo for EBV-related nasopharyngeal cancer
This trial tests a combination of three drugs (gemcitabine, docetaxel, and toripalimab) as a first treatment for a type of nasopharyngeal cancer linked to the Epstein-Barr virus. The goal is to see if this combination helps shrink tumors before other treatments like radiation.
Palo Alto, CaliforniaAges 18 years+ - NCT06682442Recruiting
Chemotherapy-guided radiation for EBV-related nasopharyngeal cancer
This trial tests whether the response to initial chemotherapy can guide the dose of radiation given to patients with Epstein-Barr virus (EBV)-associated nasopharyngeal cancer. The goal is to tailor treatment to reduce side effects while still being effective.
San Francisco, CaliforniaAges 18 years+ - NCT06702072Recruiting
Oxygen use after lung valve treatment
Researchers want to see if a bronchoscopic lung volume reduction procedure with Zephyr valves changes how much oxygen your body uses during simple tasks. You may be eligible if you are scheduled for this valve treatment and do not rely on constant oxygen for daily activities.
GroningenAges Any age - NCT07685457Recruiting
Virus-specific T cells for stubborn viral infections after transplant
This trial tests whether specially trained immune cells (virus-specific T cells) can safely treat stubborn viral infections after a stem cell transplant. It focuses on children and young adults who have not responded to standard antiviral treatments.
SeoulAges 1–25 - NCT06763289Recruiting
Comparing new blood tests for early nasopharyngeal cancer
This study is testing if a new blood test can help find nasopharyngeal cancer early. It compares different methods to see which works best. This could help people get diagnosed and treated sooner.
Guangzhou, GuangdongAges 40–75 - NCT07019870Recruiting
Screening for early diagnosis of nose cancer
This trial offers free screening to find nose cancer (nasopharyngeal carcinoma or NPC) early, before symptoms start. It is for people with a family history of NPC who may be at higher risk.
SingaporeAges 35–60 - NCT07067268RecruitingPhase 2
Tislelizumab and capecitabine for nasopharyngeal cancer with remaining EBV DNA
This trial tests a combination of two drugs, tislelizumab and capecitabine, for people with nasopharyngeal cancer who still have detectable EBV DNA in their blood after finishing radiation therapy. The goal is to see if this treatment can help clear the virus and improve outcomes.
Shanghai, ChinaAges 18 years+ - NCT07097363RecruitingPhase 2
Epcoritamab plus chemo for aggressive B-cell lymphoma
This trial tests a new drug, epcoritamab, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with aggressive B-cell non-Hodgkin lymphoma that hasn't been treated before or has had only one round of chemo. It aims to see if this combination works better against certain high-risk types of lymphoma.
Seattle, WashingtonAges 18 years+ - NCT07306156RecruitingPhase 1/Phase 2
GP350 CAR-T for Epstein-Barr virus related lymphoma
This trial tests a new treatment called GP350 CAR-T for patients with lymphoma (a type of blood cancer) that has come back or not responded to standard therapy, especially when linked to Epstein-Barr virus (EBV) infection. The therapy uses your own immune cells, modified to target and kill cancer cells carrying the GP350 protein from EBV.
Hefei, AnhuiAges 18–70 - NCT01011712Recruiting
Study immune causes of severe viral infections
This study looks at why some people have severe or unusual viral infections, even when they do not have a known immune problem. It collects blood and tissue samples to better understand possible inherited immune issues and may help future diagnosis and treatment.
Bethesda, MarylandAges 2–100 - NCT02007356RecruitingPhase 2
Donor immune cell infusions for viral infections after stem cell transplant
This trial studies whether directly infusing donor-made immune cells (virus-fighting T-cells) is safe and feasible in people who still have viral infections after a stem cell transplant. It may help your body control infections from adenovirus, CMV, or EBV when standard antiviral treatments aren’t working.
BaselAges 18–65 - NCT03159364RecruitingPhase 1/Phase 2
Immune cells for viral infections after transplant
This trial tests whether specially grown immune cells (T cells) can fight common viruses like CMV, EBV, or BK virus in people with weakened immune systems, such as after a stem cell or organ transplant. It may help when standard medicines don't work or can't be used.
Shenzhen, GuangdongAges 6 months–80 years - NCT07478952RecruitingPhase 1
EBV vaccine study for healthy adults 18 to 30
This trial tests an experimental mRNA vaccine (mRNA-1189) to see if it can prevent Epstein-Barr virus (EBV) infection. It is for healthy adults 18 to 30 years old.
Melbourne, VictoriaAges 18–30 - NCT07348575Enrolling by invitationPhase 3
Decitabine plus R-CHOP for EBV-positive DLBCL
This trial tests whether adding a drug called decitabine to the standard chemo-immunotherapy R-CHOP can help people with a specific type of lymphoma (DLBCL that is positive for EBV) who have not been treated before. The goal is to see if the combination works better than R-CHOP alone.
Nanchang, JiangxiAges 18–75 - NCT06689397Enrolling by invitation
Study of Epstein-Barr virus-related pink eye
This trial is studying a specific type of eye infection (pink eye) caused by the Epstein-Barr virus. It aims to better understand the condition and may help guide treatment for people with these symptoms.
LondonAges 16 years+
Hear when a new EBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ebv?
- Yes. Clin2 currently lists 65 recruiting ebv studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ebv trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ebv trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.